PhaseII study of the efficacy of DOCETAXEL plus RAMUCIRUMAB for NSCLC with brain metastasis
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms RAMNITA
- 01 Jun 2018 Trial design published in the Medicine.
- 19 Apr 2018 Status changed from not yet recruiting to recruiting.
- 25 Apr 2017 Planned initiation date changed from 10 Jan 2017 to 1 May 2017.